OSTX

1 BTC

=

- USD

OS Therapies Incorporated logo

OS Therapies Incorporated

OSTX🇺🇸
0.00002917
6.54%

As of May 30, 2026 at 24:05 UTC

Chart

About OS Therapies Incorporated

Sector
PHARMACEUTICAL PREPARATIONS
Headquarters
ROCKVILLE
Employees (FY)
5
Listed
2024-08-01
FIGI
BBG00Y71N7G7

OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.

Market Statistics

Market Capâ‚¿ 1.20K
24h Volumeâ‚¿ 41.65
24h Change6.54%
7d Change0.22%
1m Change28.61%

Trading Metrics

Trading Volume (BTC)â‚¿ 41.65

How to Buy OSTX

1

Create Your Account

Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.

2

Start Your Trade

From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.

3

Buy OSTX

Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.

New to Tokenized Assets? Learn more in our Help Center.

Latest News

3 articles
GlobeNewswire Inc. favicon
GlobeNewswire Inc.www.globenewswire.com

Institutional investors are rotating capital toward clinical-stage biotech companies focused on precision medicine, with the oncology precision medicine market projected to reach $303 billion by 2035. Five companies—Oncolytics Biotech, OS Therapies, Sensei Biotherapeutics, Atossa Therapeutics, and Tango Therapeutics—are advancing promising cancer treatments with strong clinical data and FDA support, positioning themselves for potential M&A activity as major pharma companies seek differentiated assets.

Benzinga favicon
Benzingawww.benzinga.com

Several biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.

Benzinga favicon
Benzingawww.benzinga.com

Analysts forecast the global oncology drug market to exceed $900 billion by 2034, with biotech firms like Oncolytics, Teva, Citius, ADC Therapeutics, and OS Therapies driving cancer treatment innovation amid potential NCI funding cuts.

1 BTC

=

- USD

Loading market data...